Research and Markets (http://www.researchandmarkets.com/reports/c91850) has announced the addition of “Concepts in Genetic Medicine” to their offering.
Concepts in Genetic Medicine offer a coherent collection of uniformly organized short reviews in the field of therapeutic genetic medicine. Each chapter focuses on a current topic (“concept”) to elucidate issues in development of genetic treatments for discuses, presenting critical challenges, strategies for addressing them, and future directions.
| Key Topics: |
| Â |
| – The Evolution of Human Gene Therapy. A Journey from Excessive Hype to Excessive Diffidence to Realty |
| – Murine Leukemia Virus Based Vectors |
| – Lentivirus Vectors |
| – Adenoviral Vectors: History and Perspective |
| – Adeno-associated Virus Vectors |
| – The Glass is Half Full: the Goal of Long-term delivery may be Approachable Using SV40-derived Vectors |
| – Herpes Simplex Virus Vectors |
| – Nonviral Gene Delivery Systems |
| – Therapeutic Gene Transfer to Skeletal Muscle |
| – Gene Therapy for Cardiovascular Disease |
| – Intra-articular Vector Delivery for Inflammatory Disease |
| – The Respiratory System as a Platform for Gene Delivery |
| – The Brain as a Target for Gene Therapy |
| – Immune Responses to Viral vectors Injected Systemically or into the CNS |
| – Cancer vaccines |
| – Genetically Modified T cells for Human Gene Therapy |
| – Lentiviral Vector Delivery of RNAi Triggers for the Treatment of HIV-1 Infection |
| – The Manufacture of Genetic Viral Vector Products |
| – The Manufacture of Adeno-associated Viral Vectors |
| – Lentivirus Vector Manufacturing |
| – Safety and Regulatory. |
| – Assays for the Release of Viral Vector Gene Therapy Products for Clinical Trials |
| – Safety of Retroviral Vectors: Regulatory and Technical Considerations |
| – Assays for the Quality Control of Lentiviral Vectors |
| – Assays for Non-viral vectors |
| – Assays for the Release of Cellular Gene Therapy Products |
| – Toxicology for Gene Therapy Products: Concepts and Challenges |
| – Regulatory Aspects of Gene Therapy Medicinal Products in the European Union |
| – Venture Capital and Biotechnology Startups |
| – The role of Investment Banking in the Growth of Biotechnology Companies |
| – Managing Reimbursment for Gene Therapy Products |
For more information visit http://www.researchandmarkets.com/reports/c91850.
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
Fax: +353 1 4100 980
